Skin adverse effects of amiodarone

Czech version

Authors: S. Zgažarová; H. Jedličková; V. Vašků
Authors‘ workplace: I. dermatovenerologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MU Dr. Vladimír Vašků, CSc.
Published in: Vnitř Lék 2009; 55(10): 976-980
Category: Case Reports

Overview

Backgro und:
Ami odarone has belonged to frequently used anti arrhythmic in the tre atment of supraventricular and ventricular tachyarrhytmi as since the sixti es of the twenti eth century. Ami odarone is a chemically i odinated benzofuran derivative with mono- N--desethylami odarone as its major metabolite. Objective: This revi ew is focused on numero us adverse re acti ons. The incidence of ami odarone induced side- effects ranges from 16– 98% of pati ents receiving ami odarone and it appe ars to be dose related. Case reports: We describe three cases of hyperpigmentati on after using ami odarone in elder men. Conclusi on: Skin side effects are common, they usu ally occur as photosensitivity, more rarely as a slate- grey discolorati on of the skin. Ami odarone induced slate- grey pigmentati on is commonly observed in unprotected light exposed skin. Its incidence ranges from 2– 57%. Hyperpigmentati on is due to accumulati on of ami odarone and its metabolites in the skin.

Key words:
ami odarone – photosensitivity – hyperpigmentati on – adverse effects

Sources

1. Hrčková Y, Šarapatková H, Lukl J. Vedlejší účinky ami odaronu. Interní Med 2005; 6: 288– 290.

2. Jiravská Godula B, Jiravský O, Vávra P et al. Nežádo ucí účinky ami odaronu. Klin Farmakol Farm 2004; 18: 171– 174.

3. Jafari- Fesharaki M, Scheinman MM. Adverse effects of ami odarone. Pacing Clin Electrophysi ol 1998; 21: 108– 120.

4. Ammo ury A, Micha ud S, Pa ul C et al. Photodistributi on of blue- gray hyperpigmentati on after ami odarone tre atment. Arch Dermatol 2008; 144: 92– 96.

5. Delage C, Lagacé R, Hu ard J. Pse udocyanotic pigmentati on of the skin induced by ami odarone: a light and electron microscopic study. Can Med Assoc J 1975; 112: 1205– 1208.

6. Dissemond J, Franckson T, Fitz G et al. Hyperpigmenti erung des Gesichts. Ha utarzt 2003; 54: 994– 998.

7. Janota T, Malík J, Holaj R et al. Méně obvyklé nežádo ucí účinky ami odaronu. Interní Med 2006; 11: 513– 514.

8. Lüllmann H, Mohr K, Wehling M. Farmakologi e a toxikologi e. 2. vyd. Praha: Grada 2004: 192– 194.

9. Shah N, Warnakulasuriya S. Ami odarone‑induced peri- oral photosensitivity. J Oral Pathol Med 2004; 33: 56– 58.

10. Bahadir S, Apaydin R, Cobano ilu Ü et al. Ami odarone pigmentati on, eye and thyro id alterati ons. J Eur Acad Dermatol Venere ol 2000; 14: 194– 195.

11. Ettler K, Gregor J, Pidrman V et al. Skin side- effects of ami odarone therapy. Sb Ved Pr Lek Fak Karlovy University Hradec Králové 1993; 36: 305– 315.

12. Lee A, Thomson J. Drug‑induced skin re acti ons. In: Lee A (ed). Adverse drug re acti ons. 2nd ed. London: Pharmace utical Press 2006: 143– 147.

13. Li AS, Chignell CF. Spectroscopic studies of cutane o us photosensitizing agents- ix. A spin trapping study of the photolysis of ami odarone and desethylami odarone. Photochem Photobi ol 1987; 45: 191– 197.

14. Yones SS, O’Donoghue NB, Palmer RA et al. Persistent severe ami odarone‑induced photosensitivity. Clin Exp Dermatol 2005; 30: 500– 502.

15. Boyer M, Katta R, Markus R. Diltiazem‑induced photodistributed hyperpigmentati on. Dermatol Online J 2003; 9: 10.

16. Jhirwal OP, Parsad D, Basu D. Skin hyperpigmentati on induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 2004; 43: 778– 779.

17. Mansani FP, Dinis TC, Carni eri EG et al. Ne utrality of ami odarone on the initi ati on and propagati on of membrane lipid peroxidati on. Cell Bi ochem Funct 1999; 17: 131– 142.

18. Ramírez- Hernández M, Martínez- Escribano JA, Martínez- Barba E et al. Cutane o us hyperpigmentati on induced by omeprazole mimicking ashy dermatosis. J Eur Acad Dermatol Venere ol 2006; 20: 584– 587.

19. Ribeiro SM, Campello AP, Nascimento AJ et al. Effect of ami odarone (AMD) on the anti oxidant enzymes, lipid peroxidati on and mitochondri al metabolism. Cell Bi ochem Funct 1997; 15: 145– 152.

20. Trappe HJ. Ami odaron. Intensivmed 2001; 38: 169– 178.

21. Jung T, Bader N, Grune T. Lipofuscin: formati on, distributi on, and metabolic consequences. Ann NY Acad Sci 2007; 1119: 97– 111.